Characteristics of asthmatics with detectable IL-32? in induced sputum - 26/07/17
Abstract |
Background |
Interleukin-32(IL-32)γ is a pro-inflammatory cytokine involved in the development and severity of chronic inflammatory diseases, but its role in asthma is unclear.
Objective |
This study was conducted to evaluate the relationship of IL-32γ levels in sputum with the severity of asthma.
Methods |
IL-32γ levels in the supernatant of induced sputum obtained from 89 patients with stable asthma were measured using a sandwich enzyme-linked immunosorbent assay (ELISA). The relationships between sputum IL-32γ levels and baseline forced expiratory volume in 1 s (FEV1% pred.), inflammatory cell profiles in sputum, and annual frequency of asthma exacerbation were determined.
Results |
IL-32γ was detected in the sputum of 25 of 89 (28.1%) asthma patients, and the levels of sputum were negatively correlated with FEV1% pred. (ρ = −0.312, p = 0.003). The annual exacerbation rate was significantly higher in this group than in the IL-32-negative group (n = 64) (p = 0.03). Sputum IL-32γ levels correlated well with the annual exacerbation rate (ρ = 0.261, p = 0.014), but there were no differences in the inflammatory cell profiles in the induced sputum of IL-32-positive and IL-32-negative patients.
Conclusion |
The level of IL-32γ in induced sputum may be associated with asthma severity and related with higher risk of asthma exacerbation.
Le texte complet de cet article est disponible en PDF.Highlights |
• | IL-32γ was measured in sputum from stable asthmatics to evaluate the association between IL-32 and severity of asthma. |
• | IL-32γ levels were correlated negatively with FEV1 and positively with annual exacerbation rates in asthma patients. |
• | Annual exacerbation rates were higher in IL-32γ detectable (+) asthmatics than in non-detectable (−) asthmatics. |
• | IL-32γ levels in sputum may be associated with asthma severity and related with higher risk of asthma exacerbation. |
Keywords : IL-32 γ, Asthma, Sputum, Severity, Exacerbation
Plan
Vol 129
P. 85-90 - août 2017 Retour au numéro
Article précédent
- Patient-perceived acceptability and behaviour change benefits of inhaler reminders and adherence feedback: A qualitative study
- Juliet M. Foster, Helen K. Reddel, Tim Usherwood, Susan M. Sawyer, Lorraine Smith
- Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®
- A. Lewis, S. Torvinen, P.N.R. Dekhuijzen, H. Chrystyn, A. Melani, Y. Zöllner, K. Kolbe, A.T. Watson, M. Blackney, A. Plich
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?